Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation

被引:0
|
作者
Kambe, Takanari [1 ]
Yamasaki, Toshinari [1 ]
Mine, Yuta [1 ]
Hagimoto, Hiroki [1 ]
Kokubun, Hidetoshi [1 ]
Kubota, Masashi [2 ]
Tsutsumi, Naofumi [1 ]
Inoue, Koji [3 ]
Hara, Shigeo [4 ]
Kawakita, Mutsushi [1 ]
机构
[1] Kobe City Med Ctr Gen Hosp, Dept Urol, Kobe, Hyogo, Japan
[2] Kyoto Univ Hosp, Dept Urol, Kyoto, Japan
[3] Kurashiki Cent Hosp, Dept Urol, Kurashiki, Okayama, Japan
[4] Kobe City Med Ctr Gen Hosp, Dept Pathol, Kobe, Hyogo, Japan
关键词
carcinomatous lymphangiosis; cytoreductive nephrectomy; immune checkpoint inhibitor; metastatic renal cell carcinoma; robot-assisted partial nephrectomy; CYTOREDUCTIVE NEPHRECTOMY;
D O I
10.1002/iju5.12427
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Cytoreductive nephrectomy has been used in combination with systemic therapy for the treatment of metastatic renal cell carcinoma, although its efficacy in the era of immune checkpoint inhibitors remains controversial. Case presentation: A 57-year-old woman was diagnosed with left renal cell carcinoma and lung carcinomatous lymphangiosis (cT3aN0M1). After receiving combined immunotherapy, she achieved complete response for the lung metastases and partial response for the primary tumor. After fivemonths of systemic therapy, she underwent partial nephrectomy to remove the primary tumor, followed by eight courses of nivolumab monotherapy. One year postoperatively, she remained recurrence-free. Conclusion: Cytoreductive partial nephrectomy for surgical consolidation may be a treatment option for metastatic renal cell carcinoma.
引用
收藏
页码:168 / 171
页数:4
相关论文
共 50 条
  • [41] Complete remission of renal cell carcinoma with lung metastases in two hemodialysis patients after low-dose interferon therapy
    Nemoto, Kaoru
    Miura, Takafumi
    Shioji, Go
    Tsuboi, Narumi
    HEMODIALYSIS INTERNATIONAL, 2011, 15 (02) : 288 - 292
  • [42] Evaluation of the Surgical Margin Threshold for Avoiding Recurrence after Partial Nephrectomy in Patients with Renal Cell Carcinoma
    Lee, Jongsoo
    Kim, Jinu
    Kim, Jong Chan
    Ham, Won Sik
    Han, Woong Kyu
    Rha, Koon Ho
    Choi, Young Deuk
    Jang, Won Sik
    YONSEI MEDICAL JOURNAL, 2022, 63 (02) : 173 - 178
  • [43] Positive surgical parenchymal margin after laparoscopic partial nephrectomy for renal cell carcinoma: Oncologic outcomes
    Permpongkosol, S
    Colombo, JR
    Gill, IS
    Kavoussi, LR
    JOURNAL OF UROLOGY, 2006, 175 (04): : 280 - 281
  • [44] Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma - A retrospective study
    Jammal, Nadya
    Pan, Eva
    Hurwitz, Michael
    Abramovitz, Rebecca B.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (03) : 556 - 563
  • [45] A case report of complete pathological remission after chemotherapy in a patient with primary renal squamous cell carcinoma
    Yu, Haiming
    Yu, Lan
    Li, Jinying
    Wang, Yu
    Liu, Li
    Zhang, Xiaotao
    Han, Xiaona
    Cheng, Xi
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (02) : 997 - 1005
  • [46] Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors
    Gul, Anita
    Stewart, Tyler F.
    Mantia, Charlene M.
    Shah, Neil J.
    Gatof, Emily Stern
    Long, Ying
    Allman, Kimberly D.
    Ornstein, Moshe C.
    Hammers, Hans J.
    McDermott, David F.
    Atkins, Michael B.
    Hurwitz, Michael
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (27) : 3088 - +
  • [47] OUTCOMES OF NEPHRECTOMY FOR RENAL CELL CARCINOMA WITH VENOUS THROMBUS FOLLOWING IMMUNE CHECKPOINT INHIBITOR THERAPY: A MULTICENTER COLLABORATIVE STUDY
    Ghoreifi, Alireza
    Gerald, Thomas
    Lee, Randall
    Howard, Jeffrey
    Asghar, Aeen
    Khanna, Abhinav
    Quinn, David
    Gill, Inderbir
    Thompson, R. Houston
    Uzzo, Robert
    Margulis, Vitaly
    Djaladat, Hooman
    JOURNAL OF UROLOGY, 2022, 207 (05): : E169 - E169
  • [48] PROGNOSTIC MODEL OF UPFRONT CYTOREDUCTIVE NEPHRECTOMY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNE-CHECKPOINT INHIBITORS AND/OR TYROSINE KINASE INHIBITORS
    Teishima, Jun
    Goto, Keisuke
    Sekino, Yohei
    Hayashi, Tetsutaro
    Hinata, Nobuyuki
    JOURNAL OF UROLOGY, 2022, 207 (05): : E169 - E170
  • [49] Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma
    Kato, Taigo
    Nagahara, Akira
    Kawamura, Norihiko
    Nakata, Wataru
    Soda, Tetsuji
    Matsuzaki, Kyosuke
    Hatano, Koji
    Kawashima, Atsunari
    Ujike, Takeshi
    Imamura, Ryoichi
    Nishimura, Kensaku
    Takada, Shingo
    Tsujihata, Masao
    Yamaguchi, Seiji
    Takao, Tetsuya
    Nakai, Yasutomo
    Nakayama, Masashi
    Nonomura, Norio
    Uemura, Motohide
    ANTICANCER RESEARCH, 2021, 41 (11) : 5811 - 5816
  • [50] Efficacy of immune checkpoint inhibitor combination therapy prior to nephrectomy in advanced renal cell carcinoma: A retrospective pilot study
    Kiyota, Sho
    Yoshida, Takashi
    Nakamoto, Takahiro
    Jino, Eri
    Mishima, Takao
    Kinoshita, Hidefumi
    BJUI COMPASS, 2024, 5 (10): : 957 - 960